RP 66784

Drug Profile

RP 66784

Alternative Names: RP 66266

Latest Information Update: 23 Sep 1997

Price : $50

At a glance

  • Originator Aventis
  • Class Antihypertensives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Hypertension

Most Recent Events

  • 23 Sep 1997 No-Development-Reported for Hypertension in France (Unknown route)
  • 23 Sep 1997 No-Development-Reported for Angina pectoris in France (Unknown route)
  • 24 Oct 1994 Preclinical development for Hypertension in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top